Nozomi MedAlliance

What Nozomi MedAlliance does

Nozomi MedAlliance is a Tokyo-based MedTech consulting and business development firm founded on November 2, 2022, with a registered capital of ¥40,804,300 and a team of 1–10 employees. The company operates a bilateral "bridge" model that connects Japanese medical device and digital health innovators with global markets and, conversely, supports foreign medical device companies seeking entry into Japan. Its offering is organized around four service pillars: (1) Global Market Entry Support — hands-on consulting for Japanese medtech firms expanding overseas, covering market research, KOL engagement, clinical needs validation, regulatory strategy (FDA/CE/ASEAN), and FTO analysis; (2) Japan Market Entry Support — advisory services for international medical device companies navigating Japanese regulatory, reimbursement, and sales-partner landscapes; (3) External Innovation — US-based R&D support leveraging TheraNova's San Francisco incubator facilities for Japanese manufacturers and distributors; and (4) Japan Incubation — transferring overseas advanced technology seeds into Japan-originated startups, including IP strategy, grant applications, and fundraising support.

The firm's competitive foundation rests on a strategic partnership with TheraNova, a San Francisco-based medical device incubator that has created 17 spin-outs and raised over $300M in private funding, providing Nozomi with direct access to the US medtech innovation ecosystem. Nozomi also maintains a portfolio of 9 medical devices and digital health products in its Japan Market Entry Pipeline spanning ophthalmology, cardiology, neurology, urology, women's health, nephrology, and addiction medicine, sourced from US and Israeli developers. Its revenue model is primarily professional services consulting fees for market entry support, supplemented by incubation and partnership fees from relationships with TheraNova and Olba Healthcare Holdings (a capital partner since May 2023). The company has no standalone software product and does not publicly disclose pricing, operating instead on customized B2B engagement models.

The company is led by Representative Director Shinya Ueda, with 20 years of finance and business development experience including prior healthcare leadership at Abdul Latif Jameel Japan, and Director Daniel Burnett (Founder/CEO of TheraNova). The team includes regulatory veteran Robert E. Claar (Heka Bio founder; 50 medical device approvals in Japan) as advisor, BD staff Yuko Terasawa and Jack Claar, and former White & Case/Orrick equity partner David Case providing legal support. Nozomi's distribution is anchored by the Tokyo-Silicon Valley MedTech Launchpad consortium (selected November 2025 for Tokyo Metropolitan Government's TOKYO SUTEAM program), participation in AMED's medical device ecosystem project with National Cancer Center Hospital East, and contracts with University of Tokyo's BioDesign program and Yamaguchi University.

Name

Nozomi MedAlliance

Legal name

Nozomi MedAlliance株式会社

Website

https://nozomimed.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Nozomi MedAlliance is a Tokyo-based MedTech consulting firm that bridges Japanese medical device startups into global markets and supports foreign medtech companies entering Japan, leveraging its TheraNova partnership, government-backed programs, and academic collaborations.

Ownership category

akta.pro rank

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Professional Services - Global Market Entry Consulting: Hands-on consulting fees for supporting Japanese medtech companies with overseas expansion, including market research, regulatory strategy, network building, and business development support
2. Professional Services - Japan Market Entry Consulting: Advisory fees for international medical device companies seeking to enter Japanese market, including regulatory compliance, insurance systems, and sales partner engagement
3. Incubation and Partnership Fees: Revenue from incubator partnership with TheraNova and strategic partnerships with healthcare companies like Olba Healthcare Holdings

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Nozomi MedAlliance provides hands-on consulting and business development services to bridge Japanese medtech companies with global markets and to help foreign medical device companies enter the Japanese market. Its offerings span four pillars: Global Market Entry Support, Japan Market Entry Support, External Innovation (US R&D via TheraNova), and Japan Incubation. The firm also operates the Tokyo-Silicon Valley MedTech Launchpad acceleration program and maintains a pipeline of foreign-developed medical devices being introduced to Japan.

Product overview

Nozomi MedAlliance is a MedTech consulting and business development firm that does not sell its own standalone software product. Its offering is a suite of professional consulting services organized around four pillars: (1) Global Market Entry — hands-on support for Japanese medtech companies expanding overseas; (2) Japan Market Entry — support for foreign medical device companies entering Japan; (3) External Innovation — US-based R&D support through Theranova partnerships; and (4) Japan Incubation — support for launching Japan-originated startups from overseas technology seeds. The company also maintains a Japan Market Entry Pipeline of medical devices and digital health products it is helping introduce to Japan from the US, Israel, and other markets, spanning therapeutic areas including ophthalmology, cardiology, neurology, urology, and diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Market Entry Support (海外展開支援)
• Japan Market Entry Support (日本市場参入支援)
• External Innovation / US R&D Support (アメリカでの研究開発)
• Japan Incubation (日本でのインキュベーション)
• Tokyo-Silicon Valley MedTech Launchpad

Quantifiable outcome

• Aiming to increase asthma clinical remission rate from 35% to over 50% through AI-supported personalized treatment

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered secondary and core.

• Investable SolutionssecondaryStrategic or Co-development Partner · 28 November 2025Consortium partner in Tokyo-Silicon Valley MedTech Launchpad program alongside TheraNova. Investable Solutions operates in Silicon Valley/Seoul/Middle East markets.
• National Cancer Center Hospital East (国立がん研究センター東病院)coreStrategic or Co-development Partner · 19 September 2025Collaboration in AMED's 'Excellent Medical Device Creation Industry Promotion Hub Enhancement Project'. Nozomi MedAlliance participates as R&D co-operator, supporting Japanese startups' US market entry through clinical/development network building, KOL engagement, clinical needs verification, and co-research opportunities.
• Carbgene (カーブジェン)secondaryStrategic or Co-development Partner · 26 August 2025Collaboration for Carbgene's AI-powered infectious disease diagnostic technology India market implementation. Nozomi provides local system analysis, PoC design, and partnership formation support for India market entry focused on AMR countermeasures.
• University of Tokyo (東京大学)coreStrategic or Co-development Partner · 4 August 2025Contracted by University of Tokyo to provide global expansion support services for medical researchers' US market entry. Collaboration with Tokyo University BioDesign program to accelerate Japanese medical technology startup creation and global expansion.
• Yamaguchi University (山口大学)secondaryStrategic or Co-development Partner · 10 June 2025Collaboration for overseas expansion of AI-powered personalized asthma treatment SaMD. AMED-supported project 'Research and Development of Machine Learning Technology for Personalized Asthma Treatment Based on Patient-Reported Outcomes'. Nozomi supports global market expansion strategy and network building.
• NCC NEXT Medical Device Development Center (国立がん研究センター東病院 NEXT医疗器械開発センター)coreStrategic or Co-development Partner · 29 October 2024Partnership for hands-on support program to revitalize Japanese medical technology overseas expansion and strengthen medtech innovation ecosystem. Started October 2024.
• SenterCare (Israel)secondaryStrategic or Co-development Partner · 9 May 2023Strategic partnership to introduce SenterCare's AI-powered non-invasive home monitoring system for elderly care to Japanese market. System uses sensors and AI analysis without cameras or wearables to provide personalized monitoring for aging populations.
• TheraNovacoreStrategic or Co-development Partner · 1 November 2022Strategic partnership with TheraNova (San Francisco-based medical device incubator) as the core of Nozomi MedAlliance's operations. TheraNova has created 17 spin-outs and raised $300M+ in private funding. Nozomi serves as TheraNova's Japan incubator partner, providing market entry support for their portfolio companies and access to US market for Japanese startups.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CMIC Group: Japan's largest CRO offering medical device development support, regulatory consulting, and clinical services. Directly comparable as both companies provide professional services bridging medtech companies with the Japanese regulatory and clinical market, though CMIC operates at substantially larger scale.
• InCROM Healthcare Japan: Japanese CRO providing clinical research and regulatory services for medical devices and pharmaceuticals. Comparable offering for medtech companies seeking professional support to enter Japanese clinical and regulatory pathways.
• EPS Holdings: Japanese CRO and healthcare services group providing medical device-related consulting, clinical research, and market entry support. Comparable business model of providing outsourced expertise to medtech and pharma companies navigating Japanese regulatory and commercial pathways.
• A2 Healthcare: Japanese CRO focused on medical device and pharmaceutical development services including regulatory affairs and clinical trials. Comparable as a specialized Japanese medtech services firm supporting foreign device companies with Japan market entry.

Regional players

• MEDINET: Japanese cell therapy and regenerative medicine services company with some medtech market entry activities. Comparable as a Japan-based medtech services firm, though focused primarily on cell therapy rather than broader medtech market entry consulting.

Broad incumbents

• M3 (M3 Inc.): Japanese digital health and healthcare platform operating physician networks, clinical trial services, and healthcare marketing. Provides some medtech market entry enablement through its MR-kun and physician panel assets, though broader in scope than Nozomi's specialization.
• Medipal Holdings: Major Japanese pharmaceutical and medical device distribution conglomerate with extensive value-added services including consulting and market development support. Operates at much larger scale but overlaps in providing foreign medical device companies with Japan market entry infrastructure.
• JAFCO Group: Japan's largest venture capital firm with active healthcare and medtech investment practice. Comparable in supporting early-stage medtech commercialization, though primarily as a capital provider rather than hands-on consulting partner.

Emerging players

• Plug and Play Japan: Japanese arm of global startup accelerator with a dedicated health/medtech vertical. Comparable in providing acceleration services and corporate-startup matching, though broader across industries and less specialized in regulatory/market entry for medical devices.
• Link-J: Tokyo-based life science community and ecosystem platform connecting academia, startups, and industry. Comparable as a connector in the Japanese life science ecosystem, though primarily a community/networking platform rather than consulting services provider.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nozomimed

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nozomi MedAlliance